ALK and non-small cell lung carcinoma: More therapies targeted to specific fusion gene/proteins have been emerging; anaplastic lymphoma kinase (ALK) is well known as a treatment target of non-small cell lung cancer, and ALK-related fusion gene is also observed in an paricular STS, i.e., inflammatory myofibroblastic tumor (IMT).